98%
921
2 minutes
20
3-Caffeoyl-4-dicaffeoylquinic acid (CDCQ) is a natural chlorogenic acid isolated from that protects against oxidative stress, inflammation, and cancer. Nitric oxide (NO) plays a physiologically beneficial role in the cardiovascular system, including vasodilation, protection of endothelial cell function, and anti-inflammation. However, the effect of CDCQ on NO production and eNOS phosphorylation in endothelial cells is unclear. We investigated the effect of CDCQ on eNOS phosphorylation and NO production in human endothelial cells, and the underlying signaling pathway. CDCQ significantly increased NO production and the phosphorylation of eNOS at Ser1177. Additionally, CDCQ induced phosphorylation of PKA, CaMKII, CaMKKβ, and AMPK. Interestingly, CDCQ increased the intracellular Ca level, and L-type Ca channel (LTCC) blockade significantly attenuated CDCQ-induced eNOS activity and NO production by inhibiting PKA, CaMKII, CaMKKβ, and AMPK phosphorylation. These results suggest that CDCQ increased eNOS phosphorylation and NO production by Ca-dependent phosphorylation of PKA, CaMKII, CaMKKβ, and AMPK. Our findings provide evidence that CDCQ plays a pivotal role in the activity of eNOS and NO production, which is involved in the protection of endothelial dysfunction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247119 | PMC |
http://dx.doi.org/10.1007/s43188-022-00121-9 | DOI Listing |
Korean J Anesthesiol
September 2025
Institute of Medical Science, Gyeongsang National University, Jinju-si, Gyeongsangnam-do, Republic of Korea.
Background: High-dose insulin and euglycemic therapy are widely used to treat calcium channel blocker toxicity. However, the effect of insulin on vasodilation evoked by the dihydropyridine calcium channel blocker amlodipine remains unknown. This study examined the effect of insulin on amlodipine-induced vasodilation in isolated rat aortas with specific emphasis on mechanisms associated with nitric oxide (NO).
View Article and Find Full Text PDFAm J Physiol Cell Physiol
September 2025
Obesity and Comorbidities Research Center, Universidade Estadual de Campinas (UNICAMP), Campinas, SP, Brazil.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially developed as glucose-lowering agents for type 2 diabetes mellitus (T2DM). However, robust clinical evidence has demonstrated that their therapeutic benefits extend beyond glycemic control. SGLT2i reduce hospitalization for heart failure (HF), slow the progression of chronic kidney disease (CKD), and provide cardiorenal protection even in individuals without diabetes but with cardiovascular disease.
View Article and Find Full Text PDFInt Immunopharmacol
September 2025
Department of Pharmacy, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China. Electronic address:
Vascular endothelial dysfunction, a form of chronic endothelial inflammation, frequently occurs in patients with diabetes, hyperlipidemia, and hyperglycemia, which is a key trigger of cardiovascular diseases. Emerging evidence has indicated that pyroptosis plays a crucial role in endothelial dysfunction and potentially represents a promising therapeutic strategy. Punicalin (PUN), a bioactive compound derived from ellagitannins, has demonstrated great potential of anti-inflammatory and anti-pyroptosis.
View Article and Find Full Text PDFNutr Metab Cardiovasc Dis
June 2025
Department of Cardiology, The Sixth Medical Center of Chinese People's Liberation Army General Hospital, No.6 Fucheng Road, Beijing, 100048, China; The School of Medicine, Nankai University, No.94 Weijin Road, Nankai District, Tianjin, 300071, China; Department of Cardiology, Chinese People's Libera
Background And Aim: This study aimed to explore the effect and potential mechanism of mineralocorticoid receptor (MR) in vascular impairment in mice with metabolic disorders(obesity and hypertension).
Methods And Results: C57BL/6 mice were used in this study. D12492 were used to fed the mice for obesity for more than 4 months and AngII was used to induce hypertension.
J Appl Physiol (1985)
August 2025
School of Kinesiology and Health Studies, Queen's University, Kingston, ON K7L3N6, Canada.
There is variability in the impact of menstrual phase on microvascular function with some studies reporting an increase from the early follicular (EF) to late follicular (LF) phase. Estradiol (E2) may increase nitric oxide bioavailability and thereby microvascular function through increasing estrogen receptor alpha (ERα), endothelial nitric oxide synthase (eNOS), and phosphorylated eNOS (p-eNOS) protein. It is unknown whether variability in ERα, eNOS, and p-eNOS protein levels drives menstrual cycle-related changes in microvascular endothelial function.
View Article and Find Full Text PDF